不可切除肝细胞癌患者的肝动脉灌注化疗：3年生存率更新
Hepatic arterial infusion chemotherapy in patients with unresectble hepatocellular carcinoma: 3-year survival update.
作者信息
Chen Shiguang, Yu Wenchang, Wang Xiaolong, Liu Weifu
机构信息
Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China.
出版信息
Hepat Oncol. 2025 Dec;12(1):2516994. doi: 10.1080/20450923.2025.2516994. Epub 2025 Jun 17.
AIMS
Hepatic arterial infusion chemotherapy (HAIC) with oxaliplatin plus raltitrexed showed a promising response rate in patients with unresectable hepatocellular carcinoma (HCC) in a phase 2 trial. Here, we report the updated 3-year survival data after enrollment.
METHODS
In this prospective trial, we enrolled patients with intermediate and advanced unresectable HCC. The treatment was HAIC with raltitrexed plus oxaliplatin.
RESULTS
The objective responses were achieved in 19 (48.7%) of 39 patients in the intention-to-treat population. The median overall survival and progress-free survival were 11.2 and 6.5 months, respectively.
CONCLUSION
The 3-year survival update confirmed the antitumor activity and long-term survival benefit of HAIC with oxaliplatin plus raltitrexed in patients with unresectable HCC.
CLINICAL TRIAL REGISTRATION
www.chictr.org.cn identifier is ChiCTR-OOC-17014182.
目的
在一项2期试验中，奥沙利铂联合雷替曲塞的肝动脉灌注化疗（HAIC）对不可切除肝细胞癌（HCC）患者显示出有前景的缓解率。在此，我们报告入组后的3年生存更新数据。
方法
在这项前瞻性试验中，我们纳入了中晚期不可切除HCC患者。治疗方案为雷替曲塞联合奥沙利铂的HAIC。
结果
在意向性治疗人群的39例患者中，19例（48.7%）获得客观缓解。中位总生存期和无进展生存期分别为11.2个月和6.5个月。
结论
3年生存更新数据证实了奥沙利铂联合雷替曲塞的HAIC对不可切除HCC患者的抗肿瘤活性和长期生存获益。
临床试验注册
Zotero 插件